Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Royalty Pharma announced the launch of the Royalty Pharma Translational Prize, a $1 million annual award recognizing exceptional achievements in translational medicine that bridge fundamental discovery and drug development. The prize will be administered independently and presented annually starting in spring 2027 at the Accelerating Bio-Innovation conference, chaired by Nobel Laureate Sir Gregory Winter.

04/21/2026, 1:00 PM • GlobeNewswire

Royalty Pharma Declares Second Quarter 2026 Dividend

Royalty Pharma plc (NASDAQ: RPRX) announced a dividend of $0.235 per Class A ordinary share for Q2 2026, payable on June 10, 2026, to shareholders of record as of May 15, 2026. The company continues to generate returns from its portfolio of royalties on over 35 commercial pharmaceutical products.

04/17/2026, 8:30 AM • Benzinga

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Zymeworks Inc. announced the appointment of Kristin Stafford as Chief Financial Officer effective April 1, 2026. Stafford brings extensive experience from Royalty Pharma in strategic planning, capital allocation, and executing complex transactions. The appointment comes as Zymeworks continues advancing its pipeline of biotherapeutics and executing strategic priorities.

04/01/2026, 6:00 AM • GlobeNewswire

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Vera Therapeutics announced the appointment of Christopher Hite, Executive Vice President and Vice Chairman of Royalty Pharma, to its Board of Directors. Hite brings over 25 years of biopharmaceutical industry experience and will serve as an independent board member as the company prepares for the potential launch of atacicept, its first-in-class dual BAFF/APRIL inhibitor for IgA nephropathy treatment.

03/05/2026, 9:00 AM • GlobeNewswire

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Royalty Pharma announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026, based in Hong Kong. The move capitalizes on the rapidly growing Asian biotech market, where Chinese medicine out-licensing reached over $130 billion in transaction value in 2025, up from $14 billion in 2021. Sun, formerly Head of Asia Pacific Healthcare Investment Banking at Morgan Stanley, will lead efforts to establish the royalty market in Asia similar to Royalty Pharma's foundational role in the Western market.

03/02/2026, 7:00 AM • GlobeNewswire

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Teva Pharmaceutical Industries will present its transformation strategy and growth outlook through 2030 at the J.P. Morgan Healthcare Conference. The company expects 2025 revenues of $16.8-$17.0 billion with operating margins of 26.2-27.1%, driven by innovative brands like AUSTEDO, AJOVY, and UZEDY. Teva targets investment-grade credit rating and projects mid-single digit revenue CAGR through 2030 with operating margins exceeding 30%. Additionally, Teva announced a $500 million agreement with Royalty Pharma to accelerate development of an anti-IL-15 candidate for vitiligo treatment.

01/11/2026, 6:00 PM • GlobeNewswire

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma and Teva announced a funding agreement of up to $500 million to accelerate clinical development of TEV-'408, an anti-IL-15 antibody candidate for vitiligo and celiac disease. The deal includes $75 million for Phase 2b funding with an option for an additional $425 million for Phase 3 development, contingent on Phase 2b results.

01/11/2026, 5:15 PM • GlobeNewswire

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva Pharmaceuticals and Royalty Pharma announced a funding agreement worth up to $500 million to accelerate clinical development of TEV-'408, an anti-IL-15 antibody candidate for vitiligo treatment. The deal includes $75 million for Phase 2b funding with an option for an additional $425 million for Phase 3 development. TEV-'408 is currently in Phase 1b for vitiligo and Phase 2a for celiac disease, addressing a significant unmet medical need with limited current treatment options.

01/11/2026, 5:00 PM • GlobeNewswire

Royalty Pharma Announces Dividend Increase

Royalty Pharma (NASDAQ: RPRX) announced a 6.8% increase in its quarterly dividend to $0.235 per Class A ordinary share for Q1 2026. The dividend will be paid on March 10, 2026 to shareholders of record as of February 20, 2026.

01/09/2026, 8:30 AM • Benzinga

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight

Merck & Co. is in advanced talks to acquire cancer drug-maker Revolution Medicines for $28-32 billion, marking potentially the largest biotech M&A deal since Pfizer's $43 billion Seagen acquisition in 2023. Revolution Medicines' stock surged 15.14% overnight on the news. The deal reflects Merck's acquisition strategy amid an industry patent cliff, following recent purchases of Cidara Therapeutics and Verona Pharma.

01/09/2026, 1:52 AM • Benzinga

What's Going On With Royalty Pharma Stock Wednesday?

Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slightly on Wednesday. The company also recently acquired royalty interests in Nuvalent's cancer drugs.

12/31/2025, 10:47 AM • Benzinga

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Royalty Pharma has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in sales-based milestones. Following the transaction, Royalty Pharma will own 100% of the tiered 8% to 16% royalty on worldwide net sales of Evrysdi, an FDA-approved spinal muscular atrophy treatment that generated approximately $1.9 billion in sales in 2024 with projected growth to $2.9 billion by 2030.

12/29/2025, 4:40 PM • Benzinga

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Cytokinetics reported strong progress towards potential FDA approval of aficamten for hypertrophic cardiomyopathy by December 26, 2025, with ongoing regulatory reviews in the U.S., China, and E.U. The company maintains a strong cash position of $1.25 billion and continues advancing multiple cardiac muscle treatment programs.

11/05/2025, 4:00 PM • GlobeNewswire

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

Royalty Pharma announced a $2.0 billion senior unsecured notes offering with three tranches: $600 million due 2031, $900 million due 2035, and $500 million due 2055. The proceeds will be used for general corporate purposes.

09/02/2025, 8:30 PM • GlobeNewswire

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

Royalty Pharma will acquire a royalty interest in Amgen's Imdelltra, a first-in-class immunotherapy for extensive-stage small cell lung cancer, for $885 million upfront with an additional potential $65 million option from BeOne Medicines.

08/25/2025, 6:10 AM • Benzinga